Theresa C. Kavanaugh

Theresa C. Kavanaugh

Theresa C. Kavanaugh

Theresa Kavanaugh is a partner in the firm’s nationally recognized Life Sciences Group. Her practice focuses on complex patent and market exclusivity strategies in anticipation of company partnering, M&A, and financing events.

Professional Activities

Dr. Kavanaugh is a member of the American Intellectual Property Law Association, the Boston Patent Law Association and the American Chemical Society.


Dr. Kavanaugh has been selected for yearly inclusion since 2013 in U.S. News-Best Lawyers for her work in the area of biotech law. She was named the 2014 Life Sciences IP Attorney of the Year in Massachusetts by Corporate Intl magazine, and has been recognized yearly as a Massachusetts Super Lawyer “Rising Star” since 2009.

Areas of Practice


Dr. Kavanaugh has significant experience in developing patent strategies throughout the developmental life cycle of chemical and biologic therapeutics. Her work includes early stage patent development for discovery programs through post approval patent strategy for FDA-approved therapeutics, including FDA Orange Book listings, patent term extension and post grant patent review procedures. She has extensive technical expertise with pharmaceutical and small molecule therapeutics; protein, antisense and other biologic therapies; diagnostic and drug discovery platform technologies, including biomarker and microbiome modulator technology; polymer chemistry; drug delivery and extended release formulations; materials science; and chemical process technologies.

Her recent representations include:

  • Proteostasis Therapeutics on patent matters relating to its cystic fibrosis transmembrane regulator program and its $50 million initial public offering
  • Aptinyx on patent matters, including patent matters related to its $65 million Series A financing
  • Naurex Inc. on patent portfolio development and patent matters relating to its NMDA small molecule and peptidyl programs and in connection with its recent $560 million merger with Allergan PLC
  • Zafgen Inc. on patent portfolio strategy and patent matters relating to its MetAP-2 small molecule program and its $96 million public offering and subsequent $137 million follow-on public offering
  • Nogra Pharma Ltd. on patent portfolio strategy and patent matters relating to its agreement with Celgene Corporation for an oral, SMAD7 antisense therapy for Crohn’s disease; the agreement includes one of the largest upfront payments for a licensing deal in the last 10 years
  • AMAG Pharmaceuticals on patent matters relating to its marketed products and its $201 million follow-on and $225 convertible note offerings
  • BIND Therapeutics on patent matters relating to its nanomedicine platform and its initial public offering on the NASDAQ Stock Market
  • Aegerion Pharmaceuticals on patent matters relating to the approved products lomitapide and metreleptin
  • Full life cycle patent strategy on behalf of a pharmaceutical company with a recently approved orphan drug
  • Early stage platform and discovery stage patent strategies for several pharmaceutical and biological therapeutic companies
  • Post grant review challenge on patents related to approved products
  • Avila Therapeutics on patent matters relating to its merger with Celgene Corporation
  • Preparation of the published patent application that includes the CAS Registry 100 millionth substance, (4S)-6-(4-chlorophenyl)-N-ethyl-8-[2-[[4[hydroxydimethylsilyl)-methyl]benzoyl]amino]ethoxy]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide



J.D., 2005
Northeastern University School of Law
Ph.D., Chemistry, 1992
Massachusetts Institute of Technology
M.L.I.S., 1997
Simmons College
M.S., Chemistry, 1987
The University of Texas at Austin
B.S., Chemistry, 1986
University of California



U.S. Patent and Trademark Office (USPTO)
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers